Larimar Therapeutics
LRMR
65 hedge funds and large institutions have $153M invested in Larimar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 8 closing their positions.
3,933% more call options, than puts
Call options by funds: $121K | Put options by funds: $3K
27% more capital invested
Capital invested by funds: $120M → $153M (+$32.8M)
0% more funds holding
Funds holding: 65 → 65 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.67% less ownership
Funds ownership: 90.2% → 89.52% (-0.67%)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$3.84M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.58M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.99M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$695K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$557K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.68M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.05M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.45M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$800K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$747K |
LRMR Hedge Fund Activity: Q3 2023 in Review
65 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2023, worth a combined $153M — up 27% from $120M a quarter earlier.
Fund positioning in LRMR was balanced in Q3 2023: 8 funds opened new positions, 8 closed out, 18 added to existing stakes and 24 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $3.84M. The largest seller was Woodline Partners, cutting an estimated $3.68M.
- 65 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $153M of Larimar Therapeutics stock for Q3 2023, up 27% quarter-over-quarter.
- 8 funds opened new Larimar Therapeutics positions in Q3 2023 and 8 closed out, a net change of 0 holders.
- The largest Larimar Therapeutics buyer in Q3 2023 was Janus Henderson Group, an estimated $3.84M added.
- The largest Larimar Therapeutics seller in Q3 2023 was Woodline Partners, an estimated $3.68M sold.
Based on aggregated 13F filings for Q3 2023.